株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

タンパク質・ペプチド経口薬市場

Oral Proteins and Peptides Market (2nd Edition), 2015 - 2025

発行 ROOTS ANALYSIS 商品コード 290265
出版日 ページ情報 英文 175 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: ROOTS ANALYSIS社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
タンパク質・ペプチド経口薬市場 Oral Proteins and Peptides Market (2nd Edition), 2015 - 2025
出版日: 2015年01月27日 ページ情報: 英文 175 Pages
概要

当レポートでは、タンパク質・ペプチド経口薬市場の現況および今後10年間の発展動向について包括的な分析を提供しており、主なケーススタディと技術プラットフォーム、競合情勢などの分析をまとめて取り上げております。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 低分子医薬品のタンパク質/ペプチド治療薬の比較
  • 投与経路
  • 開発上の課題
  • タンパク質・ペプチド経口薬

第4章 概要・市場背景

  • 本章の概要
  • 開発中のタンパク質・ペプチド経口薬
  • パイプライン分析

第5章 薬剤プロファイル・市場予測

  • イントロダクション
  • 全体市場
  • リナクロチド(Linzess/Constella)
  • プレカナチド
  • オクトレオリン
  • Ostora
  • IN-105

第6章 ケーススタディ:LIPROTAMASE、SANDIMMUNE、DDAVP

  • Liprotamase
  • Sandimmune
  • DDAVP/Minirin (デスモプレシン)

第7章 技術プラットフォーム

  • 本章の概要
  • Axcess (Proxima Concepts)
  • Peptelligence (Enteris Biopharma)
  • 胃腸透過強化技術、GIPET (Merrion Pharmaceuticals)
  • POD (タンパク質経口デリバリー)技術(Oramed Pharmaceuticals)
  • マルチマトリックスシステム(Cosmo Pharmaceuticals)
  • 経口抗体プラットフォーム(Avaxia Biologics)
  • Eligen (Emisphere Technologies)

第8章 近年の事業提携

  • 本章の概要
  • 事業提携モデル/契約
  • 利害関係者間の共同事業の普及
  • 製品開発・技術ライセンス・製品ランセンスモデル:人気の高い共同事業モデル
  • タンパク質・ペプチド経口薬の領域で最も活動的な企業

第9章 ベンチャーキャピタル支援

  • 本章の概要
  • タンパク質・ペプチド経口薬市場での投資・助成金の実例
  • ベンチャーキャピタル企業の関心の増大
  • 資金提供の実例:資金提供方式別の分布状況
  • 資金提供額:資金提供方式別の分布状況

第10章 SWOT分析

  • 本章の概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 結論

  • 複数の利害関係者からの関心の増加
  • 新技術の登場
  • 多くの適応症に推奨される提供形態
  • 新興市場は転換点に近付く
  • 課題の存在、しかし乗り越えられる

第12章 付録1:データ表

第13章 付録2:企業リスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10032

Owing to their complexity and instability, proteins and peptides are mostly injected by intravenous or subcutaneous routes. Amongst the various modes of administration, oral delivery is the more preferred route. Although very convenient, there are many challenges which hinder this route of administration. These include enzymatic and pH-dependent degradation of the amino acid based drugs in the gastrointestinal tract, low epithelial permeability and instability during formation. As a result, proteins / peptides administered orally have an extremely low (<1-2%) bioavailability.

Several developments have taken place in the recent past to develop oral formulations of such drugs. Various technologies facilitating oral administration of protein and peptide drugs are under development by a number of large / small companies across the globe. The emergence of more innovative technologies will be the key to achieving success in this field. There are many emerging proteins / peptides which are currently in preclinical / discovery stage. In addition, there are a handful of molecules which are already in late stage clinical development and are likely to become commercially available in the next few years.

The field has attracted several stakeholders including venture capital firms which have led funding rounds of many start-ups. The overall interest continues to rise as is evident from the increasing number of partnerships being forged amongst companies specialising in different areas. Product development and technology licensing agreements have been the most common and are likely to play an active role in industry's future evolution.

Synopsis:

The “Oral Proteins and Peptides Market (2nd edition), 2015-2025” report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants.

One of the key objectives of this report is to understand the current and future state oforal proteins and peptide drugs market. This was done by analyzing the following:

  • Drugs currently available in the market and those under development
  • Emerging technologies and key developments supporting the development of improved oral peptide delivery
  • Development and likely sales potential of key marketed and pipeline oral proteins and peptides

The study provides a comprehensive analysis of the competition, partnerships and key players in the market. The research, analysis and insights presented in this report include the sales forecasts of emerging oral proteins / peptides which are currently either marketed or in late stage clinical development. Our study includes proteins such as antibodies and recombinant proteins including insulin, hormones, interferon etc. However, we have excluded enzymes from our analysis. The only enzyme covered in the report is Liprotamase from Eli Lilly. Liprotamase is a pancreatic enzyme replacement therapy product. The enzyme has been presented as it differs from competing marketed drugs for being non-porcine derived and lacking an enteric coating. We have also included a special section on Liprotamase.

One of the interesting features of this report is the inclusion of case studies on two cyclic oral peptides discovered before the year 2000. These two peptides, namely Sandimmune and DDAVP, act as a role model for the biotechnology and pharmaceutical companies for future innovation and development in this field.

Example Highlights

  • 1. The market is characterized by the presence of 76 molecules in different phases of development.Four molecules are in the late stage clinical trials (phase III); of these, Oral Octreolin, Ostora and Plecanatide are likely to be made commercially available in 2016.
  • 2. Diabetes stands out among the indication groups for which various molecules are in investigational studies. Nearly 37% of the total molecules under research are being developed for diabetic disorders. Other prominent areas include gastric disorders andbone diseases.
  • 3. The market is not dominated by the presence of a big company or a group of companies. Several start-ups have led research efforts by developing the technologies that facilitate oral formulation of proteins and peptides.
  • 4. Prominent technologies include Axcess, GIPET, Peptelligence and Disulfide Rich Peptides; a number of oral proteins and peptides are based on one of these technologies.
  • 5. One of the primary drivers for growth in the industry is the rising venture capital interest and available funding from other avenues. In total, over the last 10 years, we identified total investment of close to USD 0.9 billion.
  • 6. The current crop of oral proteins and peptides is likely to benefit from early success of Linzess; combined, we expect it to be a multi-billion dollar market growing at an annualised rate of 30% over the coming decade.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. For specific studies, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides executive summary of major highlights captured in the report. It offers a high level view on the likely future of oral proteins and peptides market.

Chapter 3 provides a general introduction to the protein and peptide therapeutics market. We discuss, in detail, the available modes of administration, advantages over small molecule drugs, current challenges, and proposed solutions.

Chapter 4 provides an overview of oral proteins and peptides market with respect to marketed and pipeline drugs and companies active in the field. The analysis of the market is also extended to indications, current phase of development, and available technologies.

Chapter 5 explores various drug candidates in late stage clinical development. We have presented market data for base year 2014 (where available) and our forecasts for the period 2015 - 2025. While preparing the forecasts, several factors were taken into consideration such as status of development, competition, expected approval and likely adoption rates.

Chapter 6 presents special case studies on three molecules, namely, Liprotamase, Sandimmune and DDAVP. Sandimmune and DDAVP were launched before the year 2000 prior to the oral peptide revolution.

Chapter 7 reviewsthe major technologies available for oral protein and peptide delivery. We have presented profiles of seven leading technologies with information about their origin, mechanism, molecules using the technology and companies involved.

Chapter 8 covers details on the recent partnerships which have taken place in the industry. We have discussed the various partnerships models in existence and the most common forms of deals / agreements which have evolved over time.

Chapter 9 provides information on several funding instances which have driven research in the area of oral proteins and peptides. The analysis reveals interesting insights on the growing interest from venture capitalists and other stakeholders.

Chapter 10 provides our analysis of the strengths, weaknesses, opportunities and threats in the market, capturing the key elements likely to influence future growth.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides list of companies mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Comparison of Protein / Peptide Drugs with Small Molecule Drugs
  • 3.3. Route of Administration
    • 3.3.1. Injection: Intramuscular, Intravenous, Subcutaneous
    • 3.3.2. Transdermal
    • 3.3.3. Intranasal
    • 3.3.4. Ocular
    • 3.3.5. Inhalation
    • 3.3.6. Oral
    • 3.3.7. Implantation
  • 3.4. Development Challenges
    • 3.4.1. Instability
    • 3.4.2. Complex Purification Process
    • 3.4.3. Immunogenicity
    • 3.4.4. Side Effects
  • 3.5. Oral Proteins and Peptides
    • 3.5.1. Synopsis
    • 3.5.2. Current Challenges
    • 3.5.3. Proposed Solutions

4. OVERVIEW AND MARKET BACKGROUND

  • 4.1. Chapter Overview
  • 4.2. Oral Protein / Peptides Under Development
  • 4.3. Pipeline Analysis
    • 4.3.1. Distribution by Companies
    • 4.3.2. Distribution by Type of Molecule
    • 4.3.3. Distribution by Type of Indication
    • 4.3.4. Distribution by Phase of Development
    • 4.3.5. Distribution by Technology

5. DRUG PROFILES AND MARKET FORECAST

  • 5.1. Introduction
    • 5.1.1. Scope and Limitations
    • 5.1.2. Assumptions for Market Forecast
  • 5.2. Overall Market
  • 5.3. Linaclotide (Linzess / Constella)
    • 5.3.1. Drug Overview
    • 5.3.2. Structure and Mechanism of Action
    • 5.3.3. From Discovery to Launch
    • 5.3.4. Pharmacokinetics
    • 5.3.5. Competition
    • 5.3.6. Dosage and Cost
    • 5.3.7. Patent Portfolio
    • 5.3.8. Geographical Presence Through Partnerships
    • 5.3.9. Current Status of Development
    • 5.3.10. Linzess Sales, 2012 - 2013
    • 5.3.11. IBS-C and CIC Market
    • 5.3.12. Linaclotide (Linzess / Constella) Sales Forecast: Short-Mid Term, 2014-2019
    • 5.3.13. Linaclotide (Linzess / Constella) Sales Forecast: Long Term, 2019-2025
  • 5.4. Plecanatide
    • 5.4.1. Overview
    • 5.4.2. Structure and Mechanism of Action
    • 5.4.3. Patent
    • 5.4.4. Current Phase of Development
    • 5.4.5. Competition
    • 5.4.6. Plecanatide Sales Forecast: Short-Mid Term, 2014-2019
    • 5.4.7. Plecanatide Sales Forecast: Long Term, 2019-2025
  • 5.5. Octreolin
    • 5.5.1. Overview
    • 5.5.2. Current Treatment Options for Acromegaly
    • 5.5.3. Partnership with Roche
    • 5.5.4. Structure and Mechanism of Action
    • 5.5.5. Current Status of Development
    • 5.5.6. Competition
    • 5.5.7. Octreolin Sales Forecast: Short-Mid Term, 2014-2019
    • 5.5.8. Octreolin Sales Forecast: Long Term, 2019-2025
  • 5.6. Ostora
    • 5.6.1. Overview
    • 5.6.2. History
    • 5.6.3. Structure and Mechanism of Action
    • 5.6.4. Current Status of Development
    • 5.6.5. Competition
    • 5.6.6. Restriction on the Use of Calcitonin
    • 5.6.7. Ostora Sales Forecast: Short-Mid Term, 2014-2019
    • 5.6.8. Ostora Sales Forecast: Long Term, 2019-2025
  • 5.7. IN-105
    • 5.7.1. Overview
    • 5.7.2. History
    • 5.7.3. Structure and Mechanism of Action
    • 5.7.4. Characteristics of IN-105
    • 5.7.5. Current Status of Development
    • 5.7.6. Competition
    • 5.7.7. IN-105 Sales Forecast: Long Term, 2019-2025

6. CASE STUDIES: LIPROTAMASE, SANDIMMUNE, DDAVP

  • 6.1. Liprotamase
    • 6.1.1. Overview
    • 6.1.2. Structure and Mechanism of Action
    • 6.1.3. History
    • 6.1.4. Development Stage
    • 6.1.5. Competition
  • 6.2. Sandimmune
    • 6.2.1. Overview
    • 6.2.2. Structure and Mechanism of Action
    • 6.2.3. Discovery to Launch
    • 6.2.4. Dosage
    • 6.2.5. Patents
    • 6.2.6. Generics
    • 6.2.7. Interactions with Other Drugs
    • 6.2.8. Competition
    • 6.2.9. Sales
  • 6.3. DDAVP/Minirin (Desmopressin)
    • 6.3.1. Overview
    • 6.3.2. Structure and Mechanism of Action
    • 6.3.3. History
    • 6.3.4. Patents
    • 6.3.5. Dosage
    • 6.3.6. Pharmacokinetics
    • 6.3.7. Generics for DDAVP
    • 6.3.8. Geographical Presence
    • 6.3.9. Competition

7. TECHNOLOGY PLATFORMS

  • 7.1. Chapter Overview
  • 7.2. Axcess (Proxima Concepts)
    • 7.2.1. Overview
    • 7.2.2. Invention of Axcess
    • 7.2.3. Patents
    • 7.2.4. Technology
    • 7.2.5. Advantages
    • 7.2.6. Molecules in Pipeline
    • 7.2.7. Partnerships
  • 7.3. Peptelligence (Enteris Biopharma)
    • 7.3.1. Overview
    • 7.3.2. Recent Acquisition from Unigene Laboratories, Inc.
    • 7.3.3. Patents
    • 7.3.4. The Technology
    • 7.3.5. Advantages
    • 7.3.6. Molecules in Pipeline
    • 7.3.7. Partnerships
  • 7.4. Gastrointestinal Permeation Enhancement Technology, GIPET (Merrion Pharmaceuticals)
    • 7.4.1. Overview
    • 7.4.2. Patents
    • 7.4.3. Acquisition from Elan Biotechnology Research Centre
    • 7.4.4. Technology Platform
    • 7.4.5. Advantages of the technology
    • 7.4.6. Current Pipeline of Drugs Using GIPET
    • 7.4.7. Partner Programmes
  • 7.5. POD (Protein Oral Delivery) Technology (Oramed Pharmaceuticals)
    • 7.5.1. Overview
    • 7.5.2. Patents
    • 7.5.3. The Technology
    • 7.5.4. Advantages
    • 7.5.5. Molecules in Pipeline
    • 7.5.6. Collaborations
  • 7.6. Multi Matrix System (Cosmo Pharmaceuticals)
    • 7.6.1. Overview
    • 7.6.2. The Technology
    • 7.6.3. Patents
    • 7.6.4. Mechanism of Action
    • 7.6.5. Advantages
    • 7.6.6. Product Pipeline
    • 7.6.7. Partnerships
  • 7.7. Oral Antibody Platform (Avaxia Biologics)
    • 7.7.1. Overview
    • 7.7.2. The Technology
    • 7.7.3. Advantages
    • 7.7.4. Molecules in Pipeline
    • 7.7.5. Partnerships
  • 7.8. Eligen (Emisphere Technologies)
    • 7.8.1. Overview
    • 7.8.2. In-house Development of Eligen
    • 7.8.3. The Technology
    • 7.8.4. Advantages of Technology
    • 7.8.5. Molecules in Pipeline
    • 7.8.6. Collaborators

8. RECENT PARTNERSHIPS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models / Agreements
  • 8.3. Collaborations Amongst Stakeholders are on a Rise
  • 8.4. Product Development, Technology Licensing and Product Licensing Models Are Preferred Modes of Collaboration
  • 8.5. Most Active Companies in Oral Proteins and Peptides Area

9. VENTURE CAPITAL SUPPORT

  • 9.1. Chapter Overview
  • 9.2. Instances of Investments / Grants in Oral Protein and Peptide Drugs Market
  • 9.3. Growing Venture Capitalist Interest
  • 9.4. Funding Instances: Distribution by Type of Funding
  • 9.5. Funding Amount: Distribution by Type of Funding

10. SWOT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Strengths
  • 10.3. Weaknesses
  • 10.4. Opportunities
  • 10.5. Threats

11. CONCLUSION

  • 11.1. Growing Interest from Several Stakeholders
  • 11.2. Rise of New Technologies
  • 11.3. The Preferred Delivery Mode For a Host Of Indications
  • 11.4. An Emerging Market Close to the Tipping Point
  • 11.5. Challenges Exist, Though These can be Surpassed

12. APPENDIX 1: Tabulated Data

13. APPENDIX 2: List of Companies

List of Figures:

  • Figure 3.1: Paracellular Transport of Drugs
  • Figure 3.2: Transcellular Transport of Drugs
  • Figure 4.1: Molecules Under Development: Distribution by Companies
  • Figure 4.2: Molecules Under Development: Distribution by Type of Molecule
  • Figure 4.3: Molecules Under Development: Distribution by Type of Indication
  • Figure 4.4: Molecules Under Development: Distribution by Phase of Development
  • Figure 4.5: Molecules Under Development: Distribution by Technology
  • Figure 5.1: Overall Market of Emerging Oral Proteins / Peptides (USD Million): Short-Mid Term Forecast, 2014 - 2019 (Base Scenario)
  • Figure 5.2: Overall Market of Emerging Oral Proteins / Peptides (USD Million): Long Term Forecast, 2019 - 2025 (Base Scenario)
  • Figure 5.3: Structure of Linzess
  • Figure 5.4: Linzess Quarterly US Sales, 2013 - 2014 (USD Million)
  • Figure 5.5: US Market for IBS-C and CIC, by Drug Class, 2012 (USD Billion)
  • Figure 5.6: Linaclotide (Linzess / Constella) Sales Forecast (USD Million): Short-Mid Term, 2014-2019 (Base Scenario)
  • Figure 5.7: Linaclotide (Linzess / Constella) Sales Forecast (USD Million): Long Term, 2019-2025 (Base Scenario)
  • Figure 5.8: Structure of Plecanatide
  • Figure 5.9: Plecanatide Sales Forecast (USD Million): Short-Mid Term, 2014-2019 (Base Scenario)
  • Figure 5.10: Plecanatide Sales Forecast (USD Million): Long Term, 2019-2025 (Base Scenario)
  • Figure 5.11: Structure of Octreolin
  • Figure 5.12: Octreolin Sales Forecast (USD Million): Short-Mid Term, 2014-2019 (Base Scenario)
  • Figure 5.13: Octreolin Sales Forecast (USD Million): Long Term, 2019-2025 (Base Scenario)
  • Figure 5.14: Structure of Salmon Calcitonin
  • Figure 5.15: Ostora Sales Forecast (USD Million): Short-Mid Term, 2014-2019 (Base Scenario)
  • Figure 5.16: Ostora Sales Forecast (USD Million): Long Term, 2019-2025 (Base Scenario)
  • Figure 5.17: IN-105 Sales Forecast (USD Million): Long Term, 2019-2025 (Base Scenario)
  • Figure 6.1: Sandimmune Worldwide Sales (USD Million), 2002 - 2013
  • Figure 6.2: DDAVP Structure
  • Figure 7.1: Role of Ingredients and Excipients Used in Peptelligence Technology
  • Figure 7.2: Multifunctional Role of Absorption Enhancer in GIPET
  • Figure 7.3: MMX Technology Platform
  • Figure 8.1: Cumulative Partnerships by Year, 2006-2014
  • Figure 8.2: Oral Proteins and Peptide Partnerships: Distribution by Type of Partnership
  • Figure 8.3: Oral Proteins and Peptides Partnerships: Major Stakeholders
  • Figure 9.1: Cumulative Funding Instances by Year, 2005 onwards
  • Figure 9.2: Funding Instances: Distribution by Type of Funding
  • Figure 9.3: Funding Amount: Distribution by Type of Funding, USD Million
  • Figure 11.1: Overall Market of Emerging Oral Proteins / Peptides: Comparative Market Scenarios, 2014, 2019 and 2025 (USD Billion)

List of Tables:

  • Table 4.1: Oral Proteins / Peptides Under Development
  • Table 5.1: Emerging Oral Proteins / Peptides: Expected Launch Year of Molecules
  • Table 5.2: Marketed Drugs for IBS-C and CIC
  • Table 5.3: Linzess: Dosage and Cost
  • Table 5.4: Linzess: List of Patents
  • Table 5.5: Ironwood Partnerships for Linaclotide
  • Table 5.6: Linaclotide: Current State of Development
  • Table 5.7: Plecanatide: Patent Details
  • Table 5.8: Plecanatide: Phase IIb Clinical Trials for CIC
  • Table 5.9: Plecanatide: Phase II Clinical Trials for IBS-C
  • Table 5.10: Plecanatide vs. Linaclotide
  • Table 5.11: Plecanatide: Competitive Landscape
  • Table 5.12: Octreolin: Current State of Development
  • Table 5.13: Octreolin: Phase III Clinical Trial for Acromegaly
  • Table 5.14: Octreolin: Competitive Landscape (Approved / Marketed Drugs)
  • Table 5.15: Octreolin: Competitive Landscape (Pipeline Drugs)
  • Table 5.16: Ostora: Phase III Clinical Trials
  • Table 5.17: Ostora: Competitive Landscape
  • Table 5.18: IN-105: Status of Clinical Trials
  • Table 5.19: Oral Insulin: Molecules Under Clinical Development
  • Table 6.1: Liprotamase: Mechanism of Action
  • Table 6.2: Liprotamase: Phase III Short-term Efficacy Study
  • Table 6.3: Liprotamase: Long-term Safety Studies
  • Table 6.4: Liprotamase: Competitive Landscape
  • Table 6.5: Sandimmune: Dosage Details
  • Table 6.6: Neoral: Patent Portfolio
  • Table 6.7: Sandimmune and Neoral: List of Generic Drugs
  • Table 6.8: Sandimmune: Competitive Landscape
  • Table 6.9: DDAVP: Patent Portfolio
  • Table 6.10: DDAVP: Tablet and Oral Melts
  • Table 6.11: DDAVP: Cost of Tablets and Melts
  • Table 6.12: DDAVP Generic Versions
  • Table 6.13: DDAVP: Major Markets and Trade Names
  • Table 6.14: DDAVP: Competitive Landscape
  • Table 7.1: Axcess Patent Family
  • Table 7.2: Drugs Under Development Based on Axcess
  • Table 7.3: Bone Medical: Pipeline Drugs
  • Table 7.4: Peptelligence: Pipeline of Drugs
  • Table 7.5: GIPET Platforms
  • Table 7.6: GIPET: Pipeline of Drugs
  • Table 7.7: POD Patent Status
  • Table 7.8: POD: Molecules in Pipeline
  • Table 7.9: Drugs Based on MMX Technology
  • Table 7.10: Eligen: Pipeline of Drugs
  • Table 8.1: List of Partnerships
  • Table 9.1: List of Funding Rounds / Grants and Investors Involved
  • Table 10.1: SWOT Analysis
  • Table 12.1: Molecules Under Development: Distribution by Companies
  • Table 12.2: Molecules Under Development: Distribution by Type of Molecule
  • Table 12.3: Molecules Under Development: Distribution by Type of Indication
  • Table 12.4: Molecules Under Development: Distribution by Phase of Development
  • Table 12.5: Molecules Under Development: Distribution by Technology
  • Table 12.6: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Short-Midterm Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.7: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Short-Midterm Forecast, 2014-2019 (Base Scenario)
  • Table 12.8: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Short-Midterm Forecast, 2014-2019 (Optimistic Scenario)
  • Table 12.9: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Long Term Forecast, 2019-2025 (Conservative Scenario)
  • Table 12.10: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.11: Overall Market of Emerging Oral Proteins/Peptides (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.12: Linzess Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.13: Linzess Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Base Scenario)
  • Table 12.14: Linzess Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Optimistic Scenario)
  • Table 12.15: Linzess Sales (USD Million): Long Term Forecast, 2019-2025 (Conservative Scenario)
  • Table 12.16: Linzess Sales (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.17: Linzess Sales (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.18: Plecanatide Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.19: Plecanatide Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Base Scenario)
  • Table 12.20: Plecanatide Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Optimistic Scenario)
  • Table 12.21: Plecanatide Sales (USD Million): Long Term Forecast, 2019-2025 (Conservative Scenario)
  • Table 12.22: Plecanatide Sales (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.23: Plecanatide Sales (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.24: Octreolin Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.25: Octreolin Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Base Scenario)
  • Table 12.26: Octreolin Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Optimistic Scenario)
  • Table 12.27: Octreolin Sales (USD Million): Long Term Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.28: Octreolin Sales (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.29: Octreolin Sales (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.30: Ostora Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Conservative Scenario)
  • Table 12.31: Ostora Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Base Scenario)
  • Table 12.32: Ostora Sales (USD Million): Short-Midterm Forecast, 2014-2019 (Optimistic Scenario)
  • Table 12.33: Ostora Sales (USD Million): Long Term Forecast, 2019-2025 (Conservative Scenario)
  • Table 12.34: Ostora Sales (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.35: Ostora Sales (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.36: IN-105 Sales (USD Million): Long Term Forecast, 2019-2025 (Conservative Scenario)
  • Table 12.37: IN-105 Sales (USD Million): Long Term Forecast, 2019-2025 (Base Scenario)
  • Table 12.38: IN-105 Sales (USD Million): Long Term Forecast, 2019-2025 (Optimistic Scenario)
  • Table 12.39: Oral Proteins and Peptides: Cumulative Partnerships by Year, 2006-2014
  • Table 12.40: Oral Proteins and Peptides Partnerships: Distribution by Type of Partnerships
  • Table 12.41: Oral Proteins and Peptides: Major Stakeholders
  • Table 12.42: Cumulative Funding Instances by Year, 2005 Onwards
  • Table 12.43: Funding Instances: Distribution by Type of Funding
  • Table 12.44: Funding Amount: Distribution by Type of Funding, USD Million

List of Companies:

Following companies have been mentioned in the report:

  • 1. Abbott Laboratories
  • 2. AbbVie
  • 3. Affilogic
  • 4. AIMM Therapeutics
  • 5. Alchemia
  • 6. Almirall S.A.
  • 7. Alnara Pharmaceuticals
  • 8. Amarillo Biosciences
  • 9. Anthera Pharmaceuticals
  • 10. Apollo Life Sciences
  • 11. Apotex
  • 12. Aptalis Pharma
  • 13. Arisgen
  • 14. Armour
  • 15. Astellas
  • 16. AstraZeneca
  • 17. Avaxia Biologics
  • 18. Barr Pharmaceuticals
  • 19. Biocon
  • 20. Biodel Inc.
  • 21. Bone Medical
  • 22. Bristol-Myers Squibb
  • 23. Cara Therapeutics
  • 24. Centocor Ortho
  • 25. Chiasma Pharmaceuticals
  • 26. Clinigene
  • 27. Cosmo Pharmaceuticals
  • 28. Diabetology Ltd.
  • 29. Diasome Pharma
  • 30. Digestive Care Inc.
  • 31. Dr. Falk Pharma GmbH
  • 32. Elan Corporation
  • 33. Eli Lilly
  • 34. Emisphere Technologies
  • 35. Enteris Biopharma
  • 36. ETI Karle Clinical
  • 37. European Medical Association
  • 38. Ferring Pharmaceuticals
  • 39. Forest Laboratories
  • 40. Genentech
  • 41. Generex Biotechnology
  • 42. Genta Inc.
  • 43. Giuliani
  • 44. GlaxoSmithKline
  • 45. Hemispherx Biosciences
  • 46. Hepasome
  • 47. Hepatres Therapeutics
  • 48. Hovione
  • 49. Igy Inc.
  • 50. Inflexion
  • 51. Intrexeon Corporation
  • 52. Ipsen
  • 53. Ironwood Pharmaceuticals
  • 54. Ivax
  • 55. J&J
  • 56. Kancer
  • 57. KeyBioscience
  • 58. Kyowa Hakko
  • 59. Laser Detect Systems
  • 60. Mannkind Corporation
  • 61. Medpace Inc.
  • 62. Merck & Co.
  • 63. Meristem Therapeutics
  • 64. Merrion Pharmaceuticals
  • 65. NanoMega Medical
  • 66. NasVax
  • 67. Nektar Therapeutics
  • 68. Nobex Corporation
  • 69. Nod Pharma
  • 70. Novartis
  • 71. Novex
  • 72. Novo Nordisk
  • 73. Oramed
  • 74. Pfizer
  • 75. PlasmaTech Biopharmaceuticals
  • 76. Pliva
  • 77. PrevAbR LLC
  • 78. Protagonist Therapeutics
  • 79. Protea
  • 80. Proxima Concepts
  • 81. QS Pharma
  • 82. Rani Therapeutics
  • 83. Rebel Pharmaceuticals
  • 84. Ritter
  • 85. Roche
  • 86. Sandoz Pharmaceuticals
  • 87. Sanofi Aventis
  • 88. Santarus Inc.
  • 89. Schering-Plough
  • 90. Shire Plc
  • 91. Shreya Life Sciences
  • 92. Spofa
  • 93. Stealth Peptides
  • 94. Swiss Caps AG
  • 95. Synergy Pharma
  • 96. Synthetic Biologics
  • 97. Takeda Pharmaceuticals
  • 98. Tamarisk Technologies
  • 99. Tarix Pharma
  • 100. Tarsa Therapeutics
  • 101. Teva Pharmaceuticals
  • 102. TNT Pharma
  • 103. Transgene Biotek Limited
  • 104. Upsher-Smith Laboratories
  • 105. USFDA
  • 106. USV Limited
  • 107. Valeas
  • 108. Ventria Bioscience
  • 109. Watson Pharmaceuticals
  • 110. Zealand Pharma
  • 111. ZydusCadila

Following Universities / Research Centres have been mentioned in this report:

  • 1. Elan Biotechnology Research Centre, Trinity College, Dublin
  • 2. Biomedical Advanced Research and Development Agency
  • 3. BioScience Innovation Centre
  • 4. Hadassit Medical Research
  • 5. Tianjin International Joint Academy of Biomedicine
  • 6. University of Southern California
  • 7. National Institute of Health

Following Venture Capital firms have been mentioned in this report:

  • 1. 7 Med Health Ventures
  • 2. Abingworth
  • 3. Aegis Capital Corporation
  • 4. Alta Biopharma Partners
  • 5. ARCH Venture Partners
  • 6. Ariel Southeast Angel Partners
  • 7. Ascent Biomedical Ventures
  • 8. Beacon Angels
  • 9. Boston Harbor Angels
  • 10. Cherrystone Angels
  • 11. Connecticut Innovations
  • 12. CT Innovations
  • 13. Devon Park BioVentures
  • 14. DNA Biomedical Solutions Ltd.
  • 15. F2 Ventures
  • 16. F3 Ventures
  • 17. Foresite Capital
  • 18. Fredric Price
  • 19. GGV Capital
  • 20. Golden Seeds
  • 21. Google Ventures
  • 22. Granite State Angels
  • 23. Great Point Partners
  • 24. Healthcare Private Equity
  • 25. InCubeBioVentures
  • 26. Jerusalem Global Ventures
  • 27. Johnson and Johnson Development Corporation
  • 28. LaunchPad Venture Group
  • 29. Life Sciences Fund Amsterdam
  • 30. Lilly Ventures
  • 31. Maine Angels
  • 32. Mass Medical Angels
  • 33. Maxim Group LLC
  • 34. MHR Funding Management LLC
  • 35. Mitsubishi International Corporation
  • 36. Montaur Capital Partners
  • 37. MPM Capital
  • 38. MVM Life Science Partners
  • 39. North Country Angels
  • 40. Novo A/S
  • 41. Ofer Hi-Tech
  • 42. Oxford Finance LLC
  • 43. Pharmstandard
  • 44. QIC BioVentures
  • 45. Quaker Partners
  • 46. R.J. Kirk
  • 47. Rho Ventures
  • 48. Square 1 Bank
  • 49. Starfish Ventures
  • 50. Tech Coast Angels
  • 51. The Beta Fund
  • 52. Victory Park Capital
  • 53. Wistar Morris
  • 54. Yissum Research Development
Back to Top